Your prediction
Pluristem Therapeutics Inc. Stock
Our community identified positive and negative aspects for Pluristem Therapeutics Inc. stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Pluristem Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Pluristem Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pluristem Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pluristem Therapeutics Inc. | - | - | - | - | - | - | - |
| Oramed Pharmaceuticals | 1.210% | 10.663% | 28.842% | 8.916% | 15.677% | -66.714% | -26.532% |
| Enlivex Therapeutics Ltd. | -5.000% | -20.792% | -4.762% | -30.435% | -28.571% | -79.930% | -90.062% |
| Krystal Biotech | 0.720% | 3.678% | 18.962% | 33.718% | 37.057% | 193.803% | - |